David W Sternberg

David W Sternberg

UNVERIFIED PROFILE

Are you David W Sternberg?   Register this Author

Register author
David W Sternberg

David W Sternberg

Publications by authors named "David W Sternberg"

Are you David W Sternberg?   Register this Author

13Publications

486Reads

42Profile Views

Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis.

N Engl J Med 2016 Jun;374(26):2530-41

From the Hematology Division, Stanford University School of Medicine-Stanford Cancer Institute, Stanford, CA (J.G.); Faculty of Medical Sciences, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (H.C.K.-N.); Department of Pathology, University of New Mexico, Albuquerque (T.I.G.); Mastocytosis Center, Brigham and Women's Hospital, Boston (C.A.); Institute of Pathology, Ludwig-Maximilians-University Munich, Munich (K.S., H.-P.H.), Department of Dermatology and Venereology, University of Cologne, Cologne, and University of Luebeck, Luebeck (K.H.), and Department of Hematology and Oncology, University Hospital Mannheim of the University of Heidelberg, Mannheim (A.R.) - all in Germany; University of Paris Descartes, Institut Imagine INSERM Unité 1163 and Centre National de la Recherche Scientifique ERL8654, Centre de Reference des Mastocytoses, Paris (O.H.); Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus (F.T.A.); Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia (E.H.); Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York (M.J.M.); Novartis Pharmaceuticals, East Hanover, NJ (D.W.S., E.J.S.); Novartis Pharma, Basel, Switzerland (M.V., A.H.L.); and the Department of Internal Medicine I, Division of Hematology and Hemostaseology, and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna (P.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513098DOI Listing
June 2016

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.

Clin Cancer Res 2014 Apr 27;20(7):1935-45. Epub 2014 Jan 27.

Authors' Affiliations: Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Catalan Institute of Oncology, Barcelona, Spain; Sarah Cannon Research Institute, Nashville, Tennessee; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharmaceuticals, Florham Park, New Jersy; C.H.U. Sart-Tilman, Liege; Oncologisch Centrum AZ-St. Augustinus Oncology, Antwerp, Belgium; Novartis Pharma AG, Basel, Switzerland; Novartis Oncology, Paris, France; Memorial Sloan-Kettering Cancer Centre, New York, New York; Highlands Oncology Group, Fayetteville, Arkansas; and Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1070DOI Listing
April 2014

The molecular pathology of acute myeloid leukemia.

Hematology Am Soc Hematol Educ Program 2005 :137-42

Mt. Sinai School of Medicine, Division of Hematology/Oncology, One Gustave L. Levy Pl., Box 1079, New York, NY 10029-6504, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2005.1.137DOI Listing
November 2009

Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context.

Exp Cell Res 2007 Nov 6;313(18):3851-8. Epub 2007 Jul 6.

Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2007.06.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2099248PMC
November 2007

The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.

Blood 2007 Nov 9;110(9):3374-83. Epub 2007 Aug 9.

Klinische Abteilung für Hämatologie, Universitätsklinik für Innere Medizin, Medizinische, Universität Graz, Auenbruggerplatz 38, A-8036 Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-02-071258DOI Listing
November 2007

Quantitative proteomic analysis using isobaric protein tags enables rapid comparison of changes in transcript and protein levels in transformed cells.

Mol Cell Proteomics 2005 Jul 22;4(7):924-35. Epub 2005 Apr 22.

Department of Faculty of Medical and Human Sciences, University of Manchester, Christie Hospital, Withington, Manchester, M20 9BX, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.M400193-MCP200DOI Listing
July 2005

Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.

Curr Opin Hematol 2005 Jan;12(1):7-13

Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
January 2005

NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a.

Blood 2004 Jun 12;103(12):4622-9. Epub 2004 Feb 12.

Division of Hematology, Brigham and Women's Hospital/Harvard Medical School, 75 Francis Street, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-03-0820DOI Listing
June 2004

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.

Proc Natl Acad Sci U S A 2004 Mar 19;101(9):3130-5. Epub 2004 Feb 19.

Cancer Biology Program, Department of Medicine, Beth Israel Deaconess Medical Center, New Research Building, 330 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0400063101DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC365755PMC
March 2004

The role of signal transducer and activator of transcription factors in leukemogenesis.

J Clin Oncol 2004 Jan;22(2):361-71

Hematology Division, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2004.10.124DOI Listing
January 2004